MECOM and leukemia: A recent study showed that miR-133 binding to Evi1 increases drug sensitivity specifically in Evi1 expressing leukemic cells, suggesting that miR-133 may be a promising therapeutic target for the Evi1 dys-regulated leukemia with poor prognosis [88].